Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Erika Morsia, Paola Ranalli, Stefano Baldoni, Dorela Lame, Sonia More', Gaetano La Barba, Fabiola Saladino, Antonella Poloni, Attilio Olivieri, Serena Rupoli, Mauro Di Ianni, Shahram Kordasti

Blood (2024) 144 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2024-207881

Published: 2024

Journal Articles

High-Risk Population Screening for Gaucher Disease: Final Results and Key Learnings from an Italian Multicenter Observational Study

Irene Motta, MD, Christian Benedetto, Marina Stroppiano, Elena Cassinerio, MD, Dario Consonni, MD, Lorenza Borin, MD, Paola Ranalli, MD, Wilma Barcellini, Maria Domenica Cappellini, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-141527

Published: 2020

Journal Articles

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Blood (2020) 136 (2): 171–182.

https://doi.org/10.1182/blood.2019004596

Published: 2020

Includes: Supplemental data

Journal Articles

Von Willebrand Factor Levels in Polycythemia Vera Are Not Reduced and Can be Predicted By Erythrocyte Counts

Paola Ranalli, MD, Monica Sacco, Alfredo Dragani, MD, Mauro Di Ianni, MD PhD, Paolo Di Bartolomeo, MD, Stefano Lancellotti, PhD, Giovanna Petrucci, PhD, Bianca Rocca, MD, Raimondo De Cristofaro, MD

Blood (2017) 130 (Supplement 1): 1087.

https://doi.org/10.1182/blood.V130.Suppl_1.1087.1087

Published: 2017

Journal Articles

Poor Responsiveness to Low-Dose Aspirin Contributes to Persistent In Vivo Platelet Activation in Polycythemia Vera

Paola Ranalli, MD, Giovanna Petrucci, PhD, Alfredo Dragani, MD, Mauro Di Ianni, MD PhD, Paolo Di Bartolomeo, MD, Viviana Cavalca, BSc, Benedetta Porro, PhD, Elena Tremoli, PhD, Carlo Patrono, MD, Bianca Rocca, MD

Blood (2017) 130 (Supplement 1): 2379.

https://doi.org/10.1182/blood.V130.Suppl_1.2379.2379

Published: 2017

Journal Articles

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, MD, Alessandra Iurlo, MD, Gabriele Gugliotta, MD PhD, Alessia Tieghi, MD, Lucia Canafoglia, MD, Raffaele Palmieri, MD, Crescenza Pasciolla, MD, Nicola Vianelli, MD, Riccardo Ragionieri, Erminia Rinaldi, MD, Emilio Usala, MD, Giorgio La Nasa, MD, Alessandra Perra, MD, Giuseppe Tagariello, MD, Nilla Maschio, MD, Emma Cacciola, PhD, Rossella Rosaria Cacciola, PhD, Micaela Bergamaschi, MD, Anna Da Col, MD, Angela Rago, MD, Lorenzo Rizzo, MD, Francesco Spina, MD, Daniele Cattaneo, MD, Daniela Lambertenghi, MD, Aniello Casoria, MD, Maria Langella, Maria Luigia Randi, MD, Elisabetta Cosi, MD, Monica Crugnola, MD, Elena Masselli, MD, Paola Ranalli, MD, Giovanni Garozzo, MD, Katia Codeluppi, Oreste Villani, MD, Grazia Ferrara, Cristina Santoro, MD, Potito Rosario Scalzulli, MD, Manlio Ricciotti, MD, Viviana Appolloni, MD, Anna Candoni, MD, Annalisa Luraschi, MD, Rupoli Serena, MD, Mauro DI Ianni, MD, Giovanni Caocci, MD, Francesco Lanza, MD, Nicola Orofino, MD, Elisa Rumi, MD, Alfredo Dragani, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Umberto Santoro, Alessandro M. Vannucchi, MD PhD

Blood (2016) 128 (22): 5472.

https://doi.org/10.1182/blood.V128.22.5472.5472

Published: 2016

NARROW

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

High-Risk Population Screening for Gaucher Disease: Final Results and Key Learnings from an Italian Multicenter Observational Study

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Von Willebrand Factor Levels in Polycythemia Vera Are Not Reduced and Can be Predicted By Erythrocyte Counts

Poor Responsiveness to Low-Dose Aspirin Contributes to Persistent In Vivo Platelet Activation in Polycythemia Vera

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Email alerts

ASH Publications

American Society of Hematology

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

High-Risk Population Screening for Gaucher Disease: Final Results and Key Learnings from an Italian Multicenter Observational Study

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Von Willebrand Factor Levels in Polycythemia Vera Are Not Reduced and Can be Predicted By Erythrocyte Counts

Poor Responsiveness to Low-Dose Aspirin Contributes to Persistent In Vivo Platelet Activation in Polycythemia Vera

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only